Bailard’s ARS Pharmaceuticals SPRY Stock Holding History

Bailard’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,265	Closed	-$106K	–	786
2022 Q1	$106K	Sell	30,265 -1,735	-5%	-$7.55K	﹤0.01%	694
2021 Q4	$213K	Buy	+32,000	New	+$260K	0.01%	671

Other funds holding SPRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's SPRY Position: Q2 2022 in Review

Bailard sold out of ARS Pharmaceuticals (SPRY) in Q2 2022, closing a stake of 30,265 shares — an estimated $106K sold.

Bailard first reported a position in SPRY in Q4 2021 and held it in 2 quarters. The position peaked at $213K in Q4 2021. 64 funds tracked by Wall St. Rank hold SPRY as of Q2 2022.

Bailard reported no remaining ARS Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bailard sold 30,265 ARS Pharmaceuticals shares in Q2 2022, an estimated $106K.
Bailard first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Bailard's ARS Pharmaceuticals position peaked at $213K in Q4 2021.
64 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.